两种AR-V7检测方法性能比较
该研究比较了两种基于mRNA的AR-V7检测系统(SYBR Green与TaqMan化学法)在细胞系和32例去势抵抗性前列腺癌(CRPC)患者血样中的性能,发现两者在细胞系、系列稀释及临床样本中表现一致,诊断阈值相同且结果完全吻合,技术差异不能解释部分AR-V7阳性患者对新一代抗雄治疗的非预期反应。
要点
- 两种AR-V7 mRNA检测法在细胞系和系列稀释中表现一致,诊断阈值相同。
- 在32例CRPC患者血样中,两种检测法结果完全吻合。
- 两种方法均检出3例对新一代抗雄治疗非预期反应的AR-V7 mRNA阳性CTC患者。
核心结论
- 无论采用哪种检测方法,AR-V7 mRNA阳性的CRPC患者不应被系统性地排除在原本安全的治疗选择之外。
研究设计与样本
- 研究比较了两种基于mRNA的AR-V7检测技术(SYBR Green与TaqMan化学法),在8种泌尿生殖系肿瘤细胞系、3种AR-V7阳性前列腺癌细胞系的系列稀释液及32例CRPC患者血样中进行性能评估。
主要发现
- 两种检测法在细胞系中表现相同,系列稀释显示相同的诊断阈值。
- 在32例临床患者样本中,两种检测法结果完全吻合。
- 两种检测法均检出3例对新一代抗雄治疗非预期反应的患者的AR-V7 mRNA阳性CTC。
- 检测方法间的技术差异可被排除为部分AR-V7患者对新一代抗雄治疗非预期反应的原因。
临床怎么用
- AR-V7 mRNA阳性的CRPC患者不应仅凭检测结果被系统性地排除在原本安全的治疗选择之外。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the performance of two established androgen receptor splice variant 7 (AR-V7) mRNA detection systems, as paradoxical responses to next-generation androgen-deprivation therapy in AR-V7 mRNA-positive circulating tumour cells (CTC) of patients with castration-resistant prostate cancer (CRPC) could be related to false-positive classification using detection systems with different sensitivities. MATERIALS AND METHODS: We compared the performance of two established mRNA-based AR-V7 detection technologies using either SYBR Green or TaqMan chemistries. We assessed in vitro performance using eight genitourinary cancer cell lines and serial dilutions in three AR-V7-positive prostate cancer cell lines, as well as in 32 blood samples from patients with CRPC. RESULTS: Both assays performed identically in the cell lines and serial dilutions showed identical diagnostic thresholds. Performance comparison in 32 clinical patient samples showed perfect concordance between the assays. In particular, both assays determined AR-V7 mRNA-positive CTCs in three patients with unexpected responses to next-generation anti-androgen therapy. Thus, technical differences between the assays can be excluded as the underlying reason for the unexpected responses to next-generation anti-androgen therapy in a subset of AR-V7 patients. CONCLUSIONS: Irrespective of the method used, patients with AR-V7 mRNA-positive CRPC should not be systematically precluded from an otherwise safe treatment option.
引用
- Bernemann C, Steinestel J, Humberg V, et al. Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods. BJU Int. 2018. PMID: 29359890. doi:10.1111/bju.14146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。